Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase (n 2) and accelerated phase (n 2) CML patients received dasatinib at starting dose of 100 and 140 mg once daily, res...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Serpa, Mariana, Sanabani, Sabri S., Bendit, Israel, Seguro, Fernanda, Xavier, Flávia, Barroso, Cláudia Bitti, Conchon, Monika, Dorlhiac-Llacer, Pedro Enrique
Format: Artigo
Jezik:Inglês
Izdano: Libertas Academica 2010
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018898/
https://ncbi.nlm.nih.gov/pubmed/21234296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6413
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki